Densitometric analysis of cornea in patients with neovascular age-related macular degeneration after intravitreal aflibercept loading dose.
aflibercept
age-related macular degeneration
corneal densitometry
corneal topography
lens densitometry
specular microscopy
Journal
Therapeutic advances in ophthalmology
ISSN: 2515-8414
Titre abrégé: Ther Adv Ophthalmol
Pays: United States
ID NLM: 101728805
Informations de publication
Date de publication:
Historique:
received:
12
12
2019
accepted:
27
07
2020
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
To evaluate the anatomic changes in the cornea and anterior segment following intravitreal aflibercept loading dose for neovascular age-related macular degeneration. The study included 40 eyes of 40 patients with neovascular age-related macular degeneration. Each patient underwent a loading dose of one injection per month for three consecutive doses of aflibercept (0.05 ml/2 mg). Before and after the loading dose, a record was made for each patient of corneal topography, anterior segment, corneal densitometry, and lens densitometry parameters with the Pentacam HR and specular microscopy parameters with a non-contact specular microscope. The data before and after the aflibercept loading dose were compared. Corneal densitometry parameters in the 0- to 2-mm and 2- to 6-mm concentric zones of the posterior layer were significantly higher after the loading dose compared with baseline ( The aflibercept loading dose caused slightly increased densitometric values in some corneal regions while it did not affect the corneal topography, anterior segment, lens densitometry, and specular microscopy parameters.
Identifiants
pubmed: 32923942
doi: 10.1177/2515841420950857
pii: 10.1177_2515841420950857
pmc: PMC7457688
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2515841420950857Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4848-55
pubmed: 20435596
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Eur J Ophthalmol. 2013 Jul-Aug;23(4):504-9
pubmed: 23640509
Arch Ophthalmol. 2005 Nov;123(11):1570-4
pubmed: 16286620
Ophthalmology. 2016 Jul;123(7):1511-20
pubmed: 27084563
Cutan Ocul Toxicol. 2019 Dec;38(4):344-348
pubmed: 31092017
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Dev Ophthalmol. 2016;55:282-94
pubmed: 26501481
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3928-36
pubmed: 17724169
Ophthalmologica. 2016;236(1):43-7
pubmed: 27409826
Cornea. 2018 May;37(5):596-601
pubmed: 29384810
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2514-22
pubmed: 10937562
Eur J Ophthalmol. 2013 Sep-Oct;23(5):690-6
pubmed: 23539459
Clin Ophthalmol. 2019 Feb 15;13:373-381
pubmed: 30858687
Retina. 2015 Apr;35(4):681-6
pubmed: 25394166
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Graefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1033-9
pubmed: 24196779
BMC Ophthalmol. 2016 May 31;16:69
pubmed: 27245159
Ophthalmology. 2007 May;114(5):855-9
pubmed: 17467524
Retina. 2011 Oct;31(9):1877-84
pubmed: 21738089
Ophthalmology. 2012 Dec;119(12):2537-48
pubmed: 23084240
Am J Ophthalmol. 2017 Jan;173:56-63
pubmed: 27702624
J Cataract Refract Surg. 2016 Oct;42(10):1477-1482
pubmed: 27839603
Cornea. 2010 Aug;29(8):849-52
pubmed: 20508510
Expert Opin Investig Drugs. 2009 Oct;18(10):1573-80
pubmed: 19694600
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5
pubmed: 16156152
Invest Ophthalmol Vis Sci. 2014 Jan 07;55(1):162-8
pubmed: 24327608
Ophthalmologica. 2015;233(3-4):155-61
pubmed: 25896317
Eye (Lond). 2013 Jul;27(7):787-94
pubmed: 23722722
Am J Ophthalmol. 2008 Oct;146(4):508-12
pubmed: 18635152
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5574-8
pubmed: 26305529
Am J Ophthalmol. 2008 Nov;146(5):688-91
pubmed: 18687417